Ilhan Celik

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Eric Van Cutsem, Claus-Henning Köhne, István Láng et al. · Journal of Clinical Oncology · 2011 · 1.9K citations · Full text

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Florian Lordick, Yoon‐Koo Kang, Hyun Cheol Chung et al. · The Lancet Oncology · 2013 · 830 citations · Full text

Gastrointestinal Oncology, Advanced Gastric Cancer, Open-label Phase 3 +9

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

Carsten Bokemeyer, Eric Van Cutsem, Philippe Rougier et al. · European Journal of Cancer · 2012 · 591 citations

Gastrointestinal Oncology, Medicine, Pharmacology +9

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

Robert Pirker, Jose R. Pereira, Joachim von Pawel et al. · The Lancet Oncology · 2011 · 572 citations

Egfr Expression, Medicine, Flex Study +7

Association of <i>KRAS</i> G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

Sabine Tejpar, Ilhan Celik, Michael Schlichting et al. · Journal of Clinical Oncology · 2012 · 352 citations